Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
Public ClinicalTrials.gov record NCT00625443. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the safety and efficacy of AKR-501 (avatrombopag) administered in participants with chronic Idiopathic Thrombocytopenic Purpura (ITP) who were enrolled into and completed 28 days of study treatment in Protocol 501-CL-003 (NCT00441090).
Study identification
- NCT ID
- NCT00625443
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 53 participants
Conditions and interventions
Conditions
Interventions
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2007
- Primary completion
- May 31, 2009
- Completion
- Sep 30, 2009
- Last update posted
- Mar 15, 2018
2007 – 2009
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pacific Cancer Medical Center, Inc | Anaheim | California | 92801 | — |
| Comprehensive Blood and Cancer Center | Bakersfield | California | 93309 | — |
| Davis, Posteraro and Wasser, MDs, LLP | Manchester | Connecticut | 06105 | — |
| Florida Cancer Institute | New Port Richey | Florida | 34655 | — |
| John H. Stroger, Jr. Hospital of Cook County, Div. of Hematology and Oncology | Chicago | Illinois | 60612 | — |
| Cancer Care Center, Inc. | New Albany | Indiana | 47150 | — |
| Capitol Comprehensive Cancer Care Clinic | Jefferson City | Missouri | 65109 | — |
| Kansas City Cancer Center, LLC | Kansas City | Missouri | 64131 | — |
| Mount Sinai Medical Center | New York | New York | 10029 | — |
| New York Presbyterian Hospital, Weill Medical College of Cornell University | New York | New York | 10032 | — |
| Emerywood Oncology and Hematology | High Point | North Carolina | 27262 | — |
| Mid Ohio Oncology/Hematology, Inc., dba The Mark H. Zangmeister Center | Columbus | Ohio | 43219 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00625443, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 15, 2018 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00625443 live on ClinicalTrials.gov.